IL292186A - Compositions and methods for treating blood disorders - Google Patents
Compositions and methods for treating blood disordersInfo
- Publication number
- IL292186A IL292186A IL292186A IL29218622A IL292186A IL 292186 A IL292186 A IL 292186A IL 292186 A IL292186 A IL 292186A IL 29218622 A IL29218622 A IL 29218622A IL 292186 A IL292186 A IL 292186A
- Authority
- IL
- Israel
- Prior art keywords
- preparations
- methods
- blood disorders
- treating blood
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916492P | 2019-10-17 | 2019-10-17 | |
| PCT/US2020/056121 WO2021076991A1 (en) | 2019-10-17 | 2020-10-16 | Compositions and methods for treating blood disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292186A true IL292186A (en) | 2022-06-01 |
Family
ID=75538375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292186A IL292186A (en) | 2019-10-17 | 2022-04-12 | Compositions and methods for treating blood disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240109957A1 (enExample) |
| EP (1) | EP4045084A4 (enExample) |
| JP (2) | JP7809056B2 (enExample) |
| KR (1) | KR20220083737A (enExample) |
| CN (1) | CN114746118A (enExample) |
| AU (1) | AU2020365132A1 (enExample) |
| BR (1) | BR112022007051A2 (enExample) |
| CA (1) | CA3157873A1 (enExample) |
| IL (1) | IL292186A (enExample) |
| MX (1) | MX2022004287A (enExample) |
| WO (1) | WO2021076991A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| AU2021361067A1 (en) * | 2020-10-16 | 2023-06-01 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| CN118259018B (zh) * | 2024-03-21 | 2024-10-29 | 泰州市人民医院 | C1s抗体制备及其在ITP诊断中的应用 |
| CN119371528B (zh) * | 2024-10-30 | 2025-06-24 | 泰州市人民医院 | 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| CN106349390B (zh) * | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| PT2861246T (pt) * | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| US9382321B2 (en) * | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
-
2020
- 2020-10-16 KR KR1020227015552A patent/KR20220083737A/ko active Pending
- 2020-10-16 AU AU2020365132A patent/AU2020365132A1/en active Pending
- 2020-10-16 EP EP20877082.6A patent/EP4045084A4/en active Pending
- 2020-10-16 MX MX2022004287A patent/MX2022004287A/es unknown
- 2020-10-16 WO PCT/US2020/056121 patent/WO2021076991A1/en not_active Ceased
- 2020-10-16 CA CA3157873A patent/CA3157873A1/en active Pending
- 2020-10-16 BR BR112022007051A patent/BR112022007051A2/pt unknown
- 2020-10-16 JP JP2022522586A patent/JP7809056B2/ja active Active
- 2020-10-16 US US17/769,180 patent/US20240109957A1/en active Pending
- 2020-10-16 CN CN202080079840.5A patent/CN114746118A/zh active Pending
-
2022
- 2022-04-12 IL IL292186A patent/IL292186A/en unknown
-
2025
- 2025-10-10 JP JP2025171716A patent/JP2026028257A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022004287A (es) | 2022-07-19 |
| CA3157873A1 (en) | 2021-04-22 |
| JP2022551751A (ja) | 2022-12-13 |
| AU2020365132A1 (en) | 2022-04-28 |
| EP4045084A4 (en) | 2023-05-31 |
| KR20220083737A (ko) | 2022-06-20 |
| EP4045084A1 (en) | 2022-08-24 |
| WO2021076991A1 (en) | 2021-04-22 |
| US20240109957A1 (en) | 2024-04-04 |
| JP2026028257A (ja) | 2026-02-19 |
| JP7809056B2 (ja) | 2026-01-30 |
| CN114746118A (zh) | 2022-07-12 |
| BR112022007051A2 (pt) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304429A (en) | Methods and preparations for the treatment of epileptic disorders | |
| IL285269A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL289970A (en) | Compositions and methods for treating autoimmune disorders | |
| IL289663A (en) | Claudin18 antibodies and methods of treating cancer | |
| IL293783A (en) | Compounds and compositions for treating hematological disorders | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL290455A (en) | Methods of treating psychological and brain disorders | |
| IL284414A (en) | Methods and compositions for the treatment of fabry disease | |
| IL279748A (en) | Composition and method for treating pain | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| IL268872A (en) | Methods and compositions for treating cancers using antisense | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| IL269490B (en) | Surface treatment methods and compositions therefor | |
| IL290792A (en) | Compositions and methods for the treatment of viral infections | |
| IL291725A (en) | Methods and compositions for treating diabetic retinopathy | |
| IL290920A (en) | Methods and compositions for treating a disease or disorder | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL264070A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL282251A (en) | Compositions and methods for treatment of liver disease | |
| EP4013319A4 (en) | CELLULITE TREATMENT SYSTEM AND METHODS | |
| IL269083A (en) | Methods for preventing and treating heart disease | |
| IL290891A (en) | Compositions and methods of treating vascular diseases |